Global Synthetic Biology Market Size, Share & Trends Analysis Report By Application, By End-use, By Product, By Technology (PCR Technology, NGS Technology, Genome Editing Technology, Bioprocessing Technology and Others), By Regional Outlook and Forecast,

Global Synthetic Biology Market Size, Share & Trends Analysis Report By Application, By End-use, By Product, By Technology (PCR Technology, NGS Technology, Genome Editing Technology, Bioprocessing Technology and Others), By Regional Outlook and Forecast, 2023 - 2030

The Global Synthetic Biology Market size is expected to reach $46.7 billion by 2030, rising at a market growth of 18.7% CAGR during the forecast period.

The expansion of applications for synthetic biology, including gene editing, pathway construction, and protein engineering, may fuel the need for cloning technologies kits. Consequently, the cloning technologies kits segment would generate approximately 18.6% share of the market by 2030. These kits are essential for manipulating DNA and constructing genetic sequences. Owing to these factors, the segment will expand rapidly in the coming years.

Advanced DNA synthesis technologies enable the precise design and construction of DNA sequences. Researchers can now create custom DNA fragments with specific nucleotide sequences, optimizing the performance of synthetic biological systems. This precision is crucial for achieving desired functions in engineered organisms. Thus, these factors will drive the expansion of the market. Moreover, Synthetic biology enables the design and engineering of microorganisms to produce a wide range of bio-based materials, including bioplastics, biopolymers, and other sustainable alternatives. These materials can serve as eco-friendly substitutes for traditional plastics and petroleum-derived products. The ability to engineer microorganisms to produce bio-based fuels reduces dependency on fossil fuels. Thus, these aspects will lead to increased growth in the market.

However, Ethical considerations in synthetic biology emphasize the need for responsible research conduct. Regarding their work's potential hazards and benefits, researchers are expected to uphold ethical standards, maintain transparency, and engage in open dialogue. The public's confidence and regulatory sanction are contingent upon the responsible development and implementation of synthetic biology technologies. Environmental repercussions associated with the discharge of synthetic organisms are a source of concern. Therefore, these factors can hamper the growth of the market in the future.

However, Interruptions in procuring essential laboratory equipment, reagents, and other consumables hindered the seamless progression of research and development activities. Companies faced delays in project timelines, impacting the overall pace of innovation in the field. Therefore, the COVID-19 pandemic had a negative impact on the market.

By Application

Based on application, the market is divided into healthcare and non-healthcare. In 2022, the non-healthcare segment witnessed a substantial revenue share in the market. Synthetic biology is increasingly being applied to industrial processes, including the production of bio-based materials, chemicals, and biofuels. Companies are leveraging synthetic biology techniques to design microbes that can efficiently produce desired industrial products. Owing to these aspects, the segment will witness increased demand in the coming years.

By End-Use Analysis

By end-use, the market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and others. The biotechnology and pharmaceutical companies segment procured the highest revenue share in the market in 2022. Synthetic biology offers innovative tools and techniques that can accelerate drug discovery and development processes. Biotechnology and pharmaceutical companies leverage synthetic biology to design and engineer organisms for the production of therapeutic proteins, antibodies, and other pharmaceutical products. Thus, the segment will expand rapidly in the upcoming years.

By Product Analysis

Based on products, the market is segmented into oligonucleotide/oligo pools & synthetic DNA, enzymes, cloning technologies kits, xeno-nucleic acids, and chassis organisms. In 2022, the enzymes segment garnered a significant revenue share in the market. Enzymes play a crucial role in various industrial processes, including biofuel production, food and beverage manufacturing, and pharmaceuticals. The market may see growth in the enzymes segment as more industries adopt synthetic biology techniques to optimize and engineer enzymes for specific applications. Therefore, the segment will expand rapidly in the coming years.

By Technology Analysis

On the basis of technology, the market is divided into PCR technology, NGS technology, genome editing technology, bioprocessing technology, and others. The PCR technology segment recorded the maximum revenue share in the market in 2022. PCR is used in the assembly of biological pathways. Synthetic biology often involves the construction of novel metabolic pathways to produce desired compounds. PCR assists in the assembly and amplification of DNA fragments encoding specific enzymes or pathway components. Thus, these aspects will fuel the demand in the segment.

By Regional Analysis

By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. In 2022, the Europe segment acquired a considerable revenue share in the market. The European region boasts a strong and well-established biotechnology ecosystem. This includes a thriving biotechnology industry, a supportive regulatory environment, and collaboration between academia and industry. The presence of numerous biotech companies engaged in synthetic biology applications has contributed to the growing demand. These factors will assist in the expansion of the segment.

Recent Strategies Deployed in the Market

• Nov-2023: Twist Bioscience Corporation has launched Twist Express Genes, a cutting-edge gene synthesis service. Through this service, the company can provide customers with the same Next-Generation Sequencing (NGS)-verified, clonally perfect genes in half the usual time. Furthermore, the company has expanded the capacity of its Wilsonville facility to accommodate the increased demand for Twist Express Genes.
• Oct-2023: Thermo Fisher Scientific, Inc. has increased its production capabilities in St. Louis, Missouri, by manufacturing biologics at the facility. As a part of this expansion, the St. Louis plant will integrate up to four Thermo Scientific DynaDrive single-use bioreactors (SUB). This site will now be able to produce biologic therapies for a range of diseases such as cancers, autoimmune disorders, and rare genetic conditions.
• Sep-2023: Integrated DNA Technologies, Inc. has entered into a global distribution agreement with Aldevron, LLC, a biotechnology company. Under this agreement, the company intended to broaden the availability of essential CRISPR solutions for customers involved in cell and gene therapy. Furthermore, IDT and Aldevron are collaborating to advance CRISPR research on a global scale, jointly providing crucial solutions for translational medicine, thereby enhancing our collective contribution to the broader CRISPR community.
• May-2023: Twist Bioscience Corporation has unveiled a range of RNA sequencing tools, consisting of the Twist RNA Exome, Twist RNA Library Prep Kit, and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit. The company also offers custom target enrichment capabilities for both RNA and whole transcriptome sequencing. With this suite of RNA tools, the company aims to facilitate comprehensive transcriptome research in various fields, such as precision medicine, biomarker discovery, and immuno-oncology research.
• Feb-2023: Genscript Biotech Corporation has expanded its Singapore facility to enhance its premium gene synthesis service. This expansion will increase GenScript's ability to produce synthetic genes, addressing the growing demand from its biotech clients.
• Apr-2022: Twist Bioscience Corporation has entered into a supply agreement with Ginkgo Bio works, Inc., a horizontal platform for cell programming. This agreement signifies an extension of their collaboration within the synthetic biology ecosystem. With the growing customer base of Twist Bioscience, the aim is to ensure a stable and ample supply of high-volume DNA, leveraging the company's well-established position in the market.

List of Key Companies Profiled

• Thermo Fisher Scientific, Inc.
• Genscript Biotech Corporation
• DNA TwoPointO Inc. (Atum)
• Integrated DNA Technologies, Inc. (Danaher Corporation)
• Eurofins Scientific SE
• OriGene Technologies, Inc.
• Twist Bioscience Corporation
• Editas Medicine, Inc.
• Agilent Technologies, Inc.
• Merck KGaA

Global Synthetic Biology Market Report Segmentation

By Application

• Healthcare
• Non-healthcare

By End-use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Others

By Product

• Oligonucleotide/Oligo Pools and Synthetic DNA
• Enzymes
• Cloning Technologies Kits
• Xeno-Nucleic Acids
• Chassis Organism

By Technology

• PCR Technology
• NGS Technology
• Genome Editing Technology
• Bioprocessing Technology
• Others

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA